|
22.11.2024 08:12:36
|
GSK Plc Announces Regulatory Expansion For Arexvy In Japan To Include Adults Aged 50-59
(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include adults aged 50-59 at increased risk. Since September 2023, GSK's RSV vaccine has been approved in Japan for adults aged 60 and over. The regulatory expansion was supported by results from a global phase III trial.
The company noted that, 35 countries, including the US, have expanded approval for its RSV vaccine at increased risk population.
For More Such Health News, visit rttnews.com.
Analysen zu GlaxoSmithKline plc (GSK) (ADRS)
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Wolters Kluwer
NEU✅ American Express
NEU✅ Deckers Outdoor
inklusive Rebalancing:
❌ Synopsys
❌ Vertex Pharmaceuticals Inc
❌ Targa Resources
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Vor US-Arbeitsmarktdaten: SMI im Minus -- DAX stabil -- Asiens Börsen schliessen in RotDer heimische Aktienmarkt notiert zum Wochenende tiefer. Der deutsche Aktienmarkt bewegt sich seitwärts. In Asien notierten die Börsen am Freitag im Minus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |